News
Zydus, ICMR to Conduct Phase III Desidustat Trial for Sickle Cell Anaemia
Zydus’ Desidustat received approval from the Drug Controller General of India (DCGI) in March 2022 for the treatment of anaemia in patients with chronic kidney disease (CKD).

